Etanercept Therapy for Immune-mediated Cochleovestibular Disorders: Preliminary Results in a Pilot Study
暂无分享,去创建一个
[1] R. Spencer,et al. Low-dose Oral Methotrexate Management of Patients with Bilateral Ménière's Disease , 2000, Ear, nose, & throat journal.
[2] J. Stone,et al. Immune-mediated inner ear disease. , 2000, Current opinion in rheumatology.
[3] M. Wener,et al. Utility of Laboratory Testing in Autoimmune Inner Ear Disease , 1999, The Laryngoscope.
[4] G. Mogi,et al. Effect of proinflammatory cytokines on cultured spiral ligament fibrocytes , 1999, Hearing Research.
[5] M. Warchol. Immune cytokines and dexamethasone influence sensory regeneration in the avian vestibular periphery , 1999, Journal of neurocytology.
[6] W. Bloch,et al. Expression of inducible nitric oxide synthase (iNOS/NOS II) in the cochlea of guinea pigs after intratympanical endotoxin-treatment , 1999, Brain Research.
[7] S. Rauch,et al. Recognition of a Dominant Epitope in Bovine Heat‐Shock Protein 70 in Inner Ear Disease , 1999, The Laryngoscope.
[8] M. Warchol,et al. Macrophage secretory products influence the survival of statoacoustic neurons. , 1999, Neuroreport.
[9] J. Kremer,et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.
[10] D. Furst,et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. , 1999, Annals of internal medicine.
[11] Mikio Suzuki,et al. Successful Prevention of Retrocochlear Hearing Loss in Murine Experimental Allergic Encephalomyelitis with T Cell Receptor Vβ8–Specific Antibody , 1998, The Annals of otology, rhinology, and laryngology.
[12] M. Atlas,et al. Meniere's disease: evidence of an immune process. , 1998, American Journal of Otology.
[13] S. Rauch. Clinical Management of Immune‐mediated Inner‐ear Disease , 1997, Annals of the New York Academy of Sciences.
[14] G. Hoffman,et al. Methotrexate use in systemic vasculitis. , 1997, Rheumatic diseases clinics of North America.
[15] M. Mahalingam,et al. Antibodies to 68 kd Antigen‐Specific for Inner Ear Disease? , 1997, The Laryngoscope.
[16] E. Keithley,et al. Comparison of Anti‐Heat Shock Protein 70 (Anti‐hsp70) and Anti‐68‐kDa Inner Ear Protein in the Sera of Patients with Meniere's Disease , 1997, The Laryngoscope.
[17] C. Wise,et al. Methotrexate Management of Immune-Mediated Cochleovestibular Disorders , 1995, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[18] I. Pyykkö,et al. Azathioprine with cortisone in treatment of hearing loss in only hearing ear. , 1997, Acta oto-laryngologica. Supplementum.
[19] J. Bernstein,et al. Further observations on the role of the MHC genes and certain hearing disorders. , 1996, Acta oto-laryngologica.
[20] M. Kenmochi,et al. Antibodies of type II collagen and immune complexes in Menière's disease. , 1996, Acta oto-laryngologica. Supplementum.
[21] S. Rauch,et al. Serum antibodies to heat shock protein 70 in sensorineural hearing loss. , 1995, Archives of Otolaryngology - Head and Neck Surgery.
[22] Guy Hoffman,et al. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. , 1995, Arthritis and rheumatism.
[23] E. Keithley,et al. Evidence Linking the 68 Kilodalton Antigen Identified in Progressive Sensorineural Hearing loss Patient Sera with Heat Shock Protein 70 , 1995, The Annals of otology, rhinology, and laryngology.
[24] J. Dayer,et al. Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritis , 1995 .
[25] J. Dayer,et al. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. , 1995, Arthritis and rheumatism.
[26] J. Nadol,et al. Serum antibody to inner ear proteins in patients with progressive hearing loss. Correlation with disease activity and response to corticosteroid treatment. , 1994, JAMA.
[27] B. Beutler,et al. Unraveling function in the TNF ligand and receptor families. , 1994, Science.
[28] C A Smith,et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. , 1993, Journal of immunology.
[29] Guy Hoffman,et al. Wegener Granulomatosis: An Analysis of 158 Patients , 1992, Annals of Internal Medicine.
[30] C. Smith,et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. , 1990, Science.
[31] P. Sharp,et al. Inner ear autoantibodies in patients with rapidly progressive sensorineural hearing loss , 1990, The Laryngoscope.
[32] J. Harris,et al. The role of the endolymphatic sac in inner ear immunity. , 1987, Acta oto-laryngologica.
[33] G. Brookes. Circulating immune complexes in Meniere's disease. , 1986, Archives of otolaryngology--head & neck surgery.
[34] B. Barna,et al. Autoimmune Reactivity in Meniere'S Disease: A Preliminary Report , 1983, The Laryngoscope.
[35] J. Mathews,et al. AUTOIMMUNE SENSORINEURAL HEARING LOSS , 1980, The Lancet.